Clinical trial CANOPY-N
A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2018-004813-42 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03968419 |
| Last update |